4P-PHARMA
14.3.2024 11:36:29 CET | Business Wire | Press release
4P-Pharma, a clinical-stage biotech based in Lille dedicated to developing curative therapies for serious untreated diseases, is thrilled to announce the appointment of Jérôme Vailland as Chief Financial Officer (CFO) for 4P-Pharma and its subsidiaries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240314228336/en/
Jérôme Vailland 4P-Pharma Chief Financial Officer (Photo: Business Wire)
Jérôme Vailland built a solid career with significant contributions at Ernst & Young (EY), where he worked for 10+ years. He gained extensive experience in financial audit, company structuring, transactions, and IPOs across European and American markets, mainly in life sciences. Over the years, he held several positions up to Senior Manager, managing and advising numerous clients while assuming broader technical and managerial responsibilities.
Following his strong experience at EY, Jérôme joined Horama, now Coave Therapeutics, in 2016, serving as Chief Financial Officer. He successfully raised funds for the company by leveraging his strategic and leadership skills. In 2020, he became Chief Financial Officer of a biotechnology company listed on the Euronext Paris regulated market, focusing on developing tools and services for genome modification analysis and control.
These positions underscore his deep understanding of the financial challenges faced by public and private biotech companies and the practical solutions that must be implemented to deliver efficient results.
By joining the company's executive team, Jérôme Vailland will contribute to supporting the company's growth, especially through effective and transparent financial management. Jérôme Vailland's recognized finance skills and excellent understanding of organization structuring will be an asset for 4P-Pharma.
Revital Rattenbach, CEO of 4P-Pharma, stated: "As 4P-Pharma celebrates a decade of innovation, we welcome Jérôme Vailland as our new CFO. His experience and skills in finance are essential for our growth and transition into a successful organization. With Jérôme’s leadership, we look forward to a future of stability and continued success, reassuring our investors and partners in the pharmaceutical community of our commitment to excellence and sustainability."
Regarding his appointment as Chief Financial Officer, Jérôme Vailland said, "I am thrilled to join 4P-Pharma at a decisive moment, especially with two drug candidates prepared to enter Phase II clinical trials. I look forward to working with the team and exploring all scientific and financial options to advance the mission of 4P-Pharma and its subsidiaries."
About 4P-Pharma
Founded in 2014, 4P-Pharma is a clinical-stage biotechnology company based in Lille dedicated to developing innovative curative therapies for severe diseases with unmet medical needs. Our goal is to bring first-class therapies to patients rapidly. 4P-Pharma leverages drug candidates with reduced development timelines, thanks partly to regulatory opportunities ("emergency use" or conditional marketing authorization) with strong intellectual property. The company is based in Lille and Paris and has over 20 employees.
Website: https://4p-pharma.com/en
LinkedIn: https://www.linkedin.com/company/4p-pharma
X: https://twitter.com/4P_Pharma
The only legally binding version of the 4P-Pharma press release is the one in its original language. Translations should be compared to the source text, which takes precedence. The press release text resulting from a translation should not be considered official.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240314228336/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces closing of initial public offering2.7.2026 20:35:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the closing of its initial public offering of an aggregate of 57,971,015 of its ordinary shares, at an initial public offering price of $29.00 per share. The offering consisted of 34,398,640 shares sold by Bending Spoons and 23,572,375 shares sold by certain selling shareholders (the “Selling Shareholders”). The gross proceeds from the offering to Bending Spoons, before deducting underwriting discounts and commissions and other offering expenses, was approximately $953,917,285.50. Bending Spoons did not receive any proceeds from the sale of shares by the Selling Shareholders. Bending Spoons’ ordinary shares began trading on the Nasdaq Global Select Market on July 1, 2026 under the ticker symbol “BSP”. Goldman Sachs International, J.P. Morgan, and Allen & Company LLC are acting as joint lead book-running managers for the offering. Wells Fargo Securities, BofA Securities, Jefferies, Evercore ISI, BNP
Strategic Partnership Between Record Asset Management and Admicasa2.7.2026 19:00:00 CEST | Press release
RAM Swiss Holding AG announces a strategic partnership with Admicasa Holding AG (Admicasa). RAM Swiss Holding AG is a subsidiary of LSE-listed Record Financial Group (Record) and part of the Record Asset Management (RAM) group of companies. The partnership is a milestone in the growth of Admicasa and marks an important step in the continued expansion of Record’s private markets platform. Subject to regulatory approval, the agreement, signed on 1st July 2026, provides RAM Swiss Holding AG with a 50% participation in the Admicasa Fondsleitung AG, part of Admicasa, and establishes a long-term partnership to develop investment opportunities in the Swiss and Global real estate market with a plan to expand into other asset classes in the medium term. RAM is the European asset management arm of Record, the LSE-listed specialist investment group managing USD 115 billion of assets on behalf of institutional clients worldwide. Record's client base comprises pension funds, foundations, sovereign
IQM Quantum Computers Becomes First European Quantum Computing Company Listed on a Major U.S. Exchange2.7.2026 16:47:00 CEST | Press release
IQM begins trading on Nasdaq Global Select Market under the ticker symbol “IQMX” Company enters next phase of growth as a publicly traded leader in full-stack superconducting quantum computing IQM maintains a strong pro forma cash position of EUR 337 million IQM Quantum Computers (Nasdaq: IQMX) (“IQM”, “IQM Quantum Computers” or the “Company”), a global leader in full-stack superconducting quantum computers, today became a publicly traded company following the completion of its business combination with Real Asset Acquisition Corp. (“RAAQ”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260702960460/en/ IQM Quantum Computers Becomes First European Quantum Computing Company Listed on a Major U.S. Exchange The company’s American Depositary Shares begin trading today on the Nasdaq Global Select Market under the ticker symbol “IQMX”. The listing marks a major milestone for IQM establishing the company as the first European quan
GigaDevice Launches First GD24CL Series I²C EEPROM, Further Expanding Its Non-Volatile Memory Portfolio2.7.2026 16:00:00 CEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, announced today the launch of its new GD24CL series I²C EEPROM. The series delivers outstanding performance, comprehensive security protection mechanisms, and excellent reliability that addresses the stringent requirements for stable and long-term storage of critical configuration data. These offered features will benefit applications in industrial, energy, Internet-of-Things (IoT), data centers, and networking. As GigaDevice’s first EEPROM product series, the launch further enhances the company’s non-volatile memory portfolio and provides customers with more dynamic storage solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260702394554/en/ GigaDevice Launches First GD24CL Series I²C EEPROM, Further Expanding Its Non-Volatile Memory Portfolio. The GD24CL series is designed with high
Medical University of Graz Enrolls First Patient in DEEPER CHALLENGE Trial Evaluating Spur® Peripheral Retrievable Scaffold System in a Select CLTI Cohort2.7.2026 13:00:00 CEST | Press release
Reflow Medical, Inc. announces that the Medical University of Graz has enrolled the first patient in the DEEPER CHALLENGE clinical trial. This investigator-initiated, single-center, single-arm, prospective study, supported by a grant, investigates early vessel recoil following below-the-knee treatment using the Spur® Peripheral Retrievable Scaffold System in combination with a commercially available drug-coated balloon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701995624/en/ The study investigates early vessel recoil following below-the-knee treatment using the Spur® Peripheral Retrievable Scaffold System in combination with a commercially available drug-coated balloon. The study plans to enroll up to 40 patients with chronic limb-threatening ischemia (CLTI) across two distinct cohorts: patients with diabetes and patients with end-stage renal disease receiving hemodialysis for at least six months, with women comprisi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom